Veeva Systems
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, E...
Latest News
4 days ago · prnewswire.com
Veeva to Release Fiscal 2027 Third Quarter Results on December 3, 2026PLEASANTON, Calif., Nov. 12, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its third quarter ending October 31, 2026 after market close on December 3, 2026.
4 days ago · zacks.com
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should KnowRecently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.
6 days ago · zacks.com
Reasons to Hold Veeva Systems Stock in Your Portfolio for NowVEEV's strong Q2 results, expanding Vault CRM adoption and diversified product portfolio support growth prospects, though market saturation poses risks.
9 days ago · seekingalpha.com
Veeva Systems Inc. (VEEV) Analyst/Investor Day TranscriptVeeva Systems Inc. (VEEV) Analyst/Investor Day Transcript
11 days ago · marketbeat.com
Veeva Systems Sticks to $6 Billion Revenue Goal as AI Expands Its Market OpportunityVeeva Systems NYSE: VEEV said it remains on track to reach a $6 billion revenue run rate by calendar 2030, as the life sciences software provider expands its artificial intelligence offerings and pursues more business from clinical research organizations.
13 days ago · seekingalpha.com
Veeva: A Premium Business With More Room To CompoundVeeva System earns a Buy rating, justified by re-accelerating revenue growth, rare 45% operating margins, and sticky regulated software. VEEV trades at a 70% P/E premium to the sector but below its five-year average, with a PEG of 0.97x versus the sector median of 1.87x. Recent strategic wins include 14 of the top 20 biopharma CRM commitments and IQVIA standardizing on Veeva's clinical applications.
14 days ago · zacks.com
Why Veeva Systems (VEEV) Dipped More Than Broader Market TodayVeeva Systems (VEEV) reached $307 at the closing of the latest trading day, reflecting a -1.9% change compared to its last close.
15 days ago · zacks.com
Is It Worth Investing in Veeva (VEEV) Based on Wall Street's Bullish Views?Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
15 days ago · seekingalpha.com
Veeva Systems: Bouncing Back With A Vengeance, Still A 'Buy' Over $300Veeva Systems has rebounded strongly, outperforming prior valuation estimates as fundamentals and growth accelerate. VEEV reported FQ2 FY27 revenue of $928M, up 18% Y/Y, and GAAP operating income up 40% Y/Y, exceeding previous growth assumptions. The company achieved 70% retention of its biopharma CRM subscription base, securing all four previously undecided top-20 accounts.
19 days ago · prnewswire.com
Le Veeva Summit présente les innovations en IA et en données qui font progresser le commerce des agents/PRNewswire/ -- Veeva Systems (NYSE: VEEV) a annoncé aujourd'hui que des dirigeants d'AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche et UCB font
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VEEV